S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Sage Therapeutics Stock Forecast, Price & News

+1.23 (+1.35 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $92.44
50-Day Range
MA: $83.50
52-Week Range
Now: $92.44
Volume380,028 shs
Average Volume520,548 shs
Market Capitalization$4.81 billion
P/E RatioN/A
Dividend YieldN/A
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Sage Therapeutics logo


Overall MarketRank

1.20 out of 5 stars

Medical Sector

810th out of 1,926 stocks

Pharmaceutical Preparations Industry

407th out of 773 stocks

Analyst Opinion: 2.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SAGE



Sales & Book Value

Annual Sales$6.87 million
Book Value$18.23 per share


Net Income$-680,240,000.00
Net Margins-7,706.84%


Market Cap$4.81 billion
Next Earnings Date2/25/2021 (Estimated)
+1.23 (+1.35 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sage Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

How has Sage Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Sage Therapeutics' stock was trading at $42.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SAGE stock has increased by 118.5% and is now trading at $92.44.
View which stocks have been most impacted by COVID-19

Is Sage Therapeutics a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sage Therapeutics stock.
View analyst ratings for Sage Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Sage Therapeutics?

Wall Street analysts have given Sage Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sage Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Sage Therapeutics' CEO?

1,448 employees have rated Sage Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Sage Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Sage Therapeutics' next earnings date?

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Sage Therapeutics

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($2.03) EPS for the quarter, beating analysts' consensus estimates of ($2.30) by $0.27. The biopharmaceutical company had revenue of $1.64 million for the quarter, compared to the consensus estimate of $1.85 million. Sage Therapeutics had a negative net margin of 7,706.84% and a negative return on equity of 63.81%. The business's revenue was down 54.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.48) EPS.
View Sage Therapeutics' earnings history

What price target have analysts set for SAGE?

18 Wall Street analysts have issued 1 year price objectives for Sage Therapeutics' shares. Their forecasts range from $28.00 to $135.00. On average, they anticipate Sage Therapeutics' share price to reach $79.74 in the next year. This suggests that the stock has a possible downside of 13.7%.
View analysts' price targets for Sage Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Sage Therapeutics' key competitors?

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the following people:
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 59, Pay $536.37k)
  • Mr. Michael Cloonan, Chief Operating Officer (Age 50, Pay $582.75k)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 59, Pay $564.84k)
  • Dr. Jeffrey M. Jonas, Chief Innovation Officer, Chair of the Science & Technology Forum and Director (Age 68, Pay $983.77k)
  • Dr. Stephen J. Kanes, Chief Medical Officer (Age 56, Pay $580.67k)
  • Mr. Barry E. Greene, Pres, CEO & Director (Age 58)
  • Dr. Heinrich Schlieker Ph.D., Sr. VP of Technical Operations
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 60)
  • Mr. Matthew Calistri, VP of Investor Relations
  • Ms. Erin E. Lanciani, Sr. VP of People & Organizational Strategy (Age 52)

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Exchange Traded Concepts LLC (0.02%), Westside Investment Management Inc. (0.01%), Arthur M. Cohen & Associates LLC (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul.
View institutional ownership trends for Sage Therapeutics

Which institutional investors are selling Sage Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Westside Investment Management Inc., and Pacer Advisors Inc..
View insider buying and selling activity for Sage Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Sage Therapeutics stock?

SAGE stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and Arthur M. Cohen & Associates LLC. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sage Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $92.44.

How big of a company is Sage Therapeutics?

Sage Therapeutics has a market capitalization of $4.81 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. Sage Therapeutics employs 675 workers across the globe.

What is Sage Therapeutics' official website?

The official website for Sage Therapeutics is www.sagerx.com.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.